Clinical Development of ADC Drugs Targeting TROP-2.pdfDoriaFang
TROP-2 is expressed in many tumor types, making it an emerging and popular target for ADC development. This article introduces clinical development of ADC drugs targeting TROP-2.
Clinical Development of ADC Drugs Targeting TROP-2.pdfDoriaFang
TROP-2 is expressed in many tumor types, making it an emerging and popular target for ADC development. This article introduces clinical development of ADC drugs targeting TROP-2.
Epigenetic regulation and role of metastasis suppressor genes in pancreatic d...Enrique Moreno Gonzalez
Pancreatic ductal adenocarcinoma (PDAC) is distinguished by rapid dissemination. Thus, genetic and/or epigenetic deregulation of metastasis suppressor genes (MSG) is a likely event during early pancreatic carcinogenesis and a potential diagnostic marker for the disease. We investigated 9 known MSGs for their role in the dissemination of PDAC and examined their promoters for methylation and its use in PDAC detection.
Cancer is a complex disease characterized by the uncontrolled growth and spread of abnormal cells in the body. Despite significant advancements in cancer treatment over the years, it remains a major public health concern and a leading cause of death worldwide. Therefore, there is an urgent need for the development of new therapeutic agents to improve cancer treatment outcomes.
Modern Strategies in Cancer Study: Drug Repositioning in Colorectal Cancer Tr...CrimsonpublishersCancer
Colorectal cancer is one of the most fatal cancers in the world because most of cases are diagnosed in advanced stages, when the development of resistance to chemotherapy is more frequent. To face this situation, new drugs and drug combinations would be necessary. Drug discovery is a very costly process; although efforts in drug discovery have been amplified in recent decades the success rate of approved FDA drugs continues being low. In response to this situation the repositioning of drugs proposes to delve into the genetic, epigenetic and metabolic differences to discover new targets and redirect drugs already approved to the treatment of other diseases and conditions. In this minireview we discuss the main avenues in which repositioning can occur and we cite some examples of repositioning drugs in colorectal cancer treatment that are being tested in clinical trials in the past years.
Precision medicine is a rapidly growing field of medicine that proposes individually customized diagnostics and therapeutics based upon molecular and genetic profile of individual patients. The main goal of precision medicine is to minimize harmful side effects and maximize benefits. In particular, hematological malignancies were seen as the most direct candidates of the most promising applications of precision medicine. However, Precision medicine approaches face multiple challenges. Despite these challenges and limitations, continuous effort is carried out to use these molecular findings as disease biomarkers and targets for therapeutic intervention. In the last decade the hemato-oncology witnessed a major revolution in the understanding of the molecular pathogenesis of hematological malignancies. While the therapeutic research for hematologic malignancies is continuously expanding, some medicines have been approved in hematological malignancies patients’ therapeutic algorithm and many are still under investigation.
Background : During the conference of ASCO 2015, there was no consensus about TIL role in beast cancer and no recommendations concerning the microscopic assessment of TIL. In fact, the patients could be put on anti-PD1 drugs without the necessity of highlighting PD1 positive cells by using immunohistochemistry. Nevertheless, many questions about the prognostic impact of TIL, the methods of assessment, the type of TIL to count remain unresolved. Material and Methods : We performed a review of the literature on the sites : Pubmed and Cochrane. We used the key-words : �TIL in cancer�; �TIL in breast cancer� and �prognostic impact of TIL in breast cancer�. Results : According to our inclusion and exclusion criteria, thirty eight articles were retained. Our review of the literature showed that assessing TIL in high grade tumors seem unnecessary. They seem available in intermediate graded tumors. In neo-adjuvant and adjuvant conditions, CD3+ lymphocytes seem to be correlated to a good response to chemotherapy. After a chemotherapy, quantification T reg lymphocytes CD4 + FOXP3+ seems helpful because the decrease of their number is correlated to a good prognosis. Conclusion : The role of TIL in breast cancer is clearly established. The mechanisms of immune escape induced to discovery of immune therapy. The role of the microscopic examination and the subtyping of TIL using immunohistochemistry hasn�t been clearly established. Through this review of the literature, we tried to establish a diagram highlighting the different subtypes of TIL to evaluate and their prognostic impact.
Trophoblast Glycoprotein (TPGB5T4) A New Target For ADC Drugs.pdfDoriaFang
The more popular targets in ADC drugs include HER2, TROP2, EGFR, CLDN18.2, c-Met, CD19, PSMA, Muc1, BCMA and PDL1. Here we will introduce a new ADC target trophoblast glycoprotein (TPBG).
Deadenylase Expression in Small Cell Lung Cancer Related To Clinical Characte...JohnJulie1
Lung cancer is the second common malignancy and the most aggressive cancer worldwide with late diagnosis and poor prognosis. The search for biomarkers that promote early diagnosis and improve therapeutic strategies focuses to the understanding of the mechanisms underlying cancer development and progression. The deregulation of gene expression is one of the cancer hallmarks reflected to the stability...
Deadenylase Expression in Small Cell Lung Cancer Related To Clinical Characte...AnonIshanvi
Lung cancer is the second common malignancy and the most aggressive cancer worldwide with late diagnosis and poor prognosis. The search for biomarkers that promote early diagnosis and improve therapeutic strategies focuses to the understanding of the mechanisms underlying cancer development and progression
Deadenylase Expression in Small Cell Lung Cancer Related To Clinical Characte...daranisaha
Lung cancer is the second common malignancy and the most aggressive cancer worldwide with late diagnosis and poor prognosis. The search for biomarkers that promote early diagnosis and improve therapeutic strategies focuses to the understanding of the mechanisms underlying cancer development and progression. The deregulation of gene expression is one of the cancer hallmarks reflected to the stability...
Deadenylase Expression in Small Cell Lung Cancer Related To Clinical Characte...EditorSara
Lung cancer is the second common malignancy and the most aggressive cancer worldwide with late diagnosis and poor prognosis. The search for biomarkers that promote early diagnosis and improve therapeutic strategies focuses to the understanding of the mechanisms underlying cancer development and progression. The deregulation of gene expression is one of the cancer hallmarks reflected to the stability..
Deadenylase Expression in Small Cell Lung Cancer Related To Clinical Characte...NainaAnon
Lung cancer is the second common malignancy and the most aggressive cancer worldwide with late diagnosis and poor prognosis. The search for biomarkers that promote early diagnosis and improve therapeutic strategies focuses to the understanding of the mechanisms underlying cancer development and progression. The deregulation of gene expression is one of the cancer hallmarks reflected to the stability...
Deadenylase Expression in Small Cell Lung Cancer Related To Clinical Characte...semualkaira
Lung cancer is the second common malignancy and the most aggressive cancer worldwide with late diagnosis and poor prognosis. The search for biomarkers that promote early diagnosis and improve therapeutic strategies focuses to the understanding of the mechanisms underlying cancer development and progression. The deregulation of gene expression is one of the cancer hallmarks reflected to the stability...
Cyclic Peptides Current Status & Future Prospects.pdfDoriaFang
Researchers have made unremitting efforts to optimize peptides in order to improve the bioavailability of peptide drugs. Cyclization of peptides is one of the methods to optimize peptides. Cyclic peptides combine several favorable properties such as good binding affinity, target selectivity and low toxicity that make them an attractive modality for the development of therapeutics.
Antibody–Oligonucleotide Conjugates (AOCs) in Clinical Trials.pdfDoriaFang
Summary of Antibody–Oligonucleotide Conjugates(AOCs) in Clinical Trials, including products from Avidity Biosciences, Dyne Therapeutics, Tallac Therapeutics and Denali Therapeutics.
More Related Content
Similar to Overview of New Targets For Anti-tumor Drugs.pdf
Epigenetic regulation and role of metastasis suppressor genes in pancreatic d...Enrique Moreno Gonzalez
Pancreatic ductal adenocarcinoma (PDAC) is distinguished by rapid dissemination. Thus, genetic and/or epigenetic deregulation of metastasis suppressor genes (MSG) is a likely event during early pancreatic carcinogenesis and a potential diagnostic marker for the disease. We investigated 9 known MSGs for their role in the dissemination of PDAC and examined their promoters for methylation and its use in PDAC detection.
Cancer is a complex disease characterized by the uncontrolled growth and spread of abnormal cells in the body. Despite significant advancements in cancer treatment over the years, it remains a major public health concern and a leading cause of death worldwide. Therefore, there is an urgent need for the development of new therapeutic agents to improve cancer treatment outcomes.
Modern Strategies in Cancer Study: Drug Repositioning in Colorectal Cancer Tr...CrimsonpublishersCancer
Colorectal cancer is one of the most fatal cancers in the world because most of cases are diagnosed in advanced stages, when the development of resistance to chemotherapy is more frequent. To face this situation, new drugs and drug combinations would be necessary. Drug discovery is a very costly process; although efforts in drug discovery have been amplified in recent decades the success rate of approved FDA drugs continues being low. In response to this situation the repositioning of drugs proposes to delve into the genetic, epigenetic and metabolic differences to discover new targets and redirect drugs already approved to the treatment of other diseases and conditions. In this minireview we discuss the main avenues in which repositioning can occur and we cite some examples of repositioning drugs in colorectal cancer treatment that are being tested in clinical trials in the past years.
Precision medicine is a rapidly growing field of medicine that proposes individually customized diagnostics and therapeutics based upon molecular and genetic profile of individual patients. The main goal of precision medicine is to minimize harmful side effects and maximize benefits. In particular, hematological malignancies were seen as the most direct candidates of the most promising applications of precision medicine. However, Precision medicine approaches face multiple challenges. Despite these challenges and limitations, continuous effort is carried out to use these molecular findings as disease biomarkers and targets for therapeutic intervention. In the last decade the hemato-oncology witnessed a major revolution in the understanding of the molecular pathogenesis of hematological malignancies. While the therapeutic research for hematologic malignancies is continuously expanding, some medicines have been approved in hematological malignancies patients’ therapeutic algorithm and many are still under investigation.
Background : During the conference of ASCO 2015, there was no consensus about TIL role in beast cancer and no recommendations concerning the microscopic assessment of TIL. In fact, the patients could be put on anti-PD1 drugs without the necessity of highlighting PD1 positive cells by using immunohistochemistry. Nevertheless, many questions about the prognostic impact of TIL, the methods of assessment, the type of TIL to count remain unresolved. Material and Methods : We performed a review of the literature on the sites : Pubmed and Cochrane. We used the key-words : �TIL in cancer�; �TIL in breast cancer� and �prognostic impact of TIL in breast cancer�. Results : According to our inclusion and exclusion criteria, thirty eight articles were retained. Our review of the literature showed that assessing TIL in high grade tumors seem unnecessary. They seem available in intermediate graded tumors. In neo-adjuvant and adjuvant conditions, CD3+ lymphocytes seem to be correlated to a good response to chemotherapy. After a chemotherapy, quantification T reg lymphocytes CD4 + FOXP3+ seems helpful because the decrease of their number is correlated to a good prognosis. Conclusion : The role of TIL in breast cancer is clearly established. The mechanisms of immune escape induced to discovery of immune therapy. The role of the microscopic examination and the subtyping of TIL using immunohistochemistry hasn�t been clearly established. Through this review of the literature, we tried to establish a diagram highlighting the different subtypes of TIL to evaluate and their prognostic impact.
Trophoblast Glycoprotein (TPGB5T4) A New Target For ADC Drugs.pdfDoriaFang
The more popular targets in ADC drugs include HER2, TROP2, EGFR, CLDN18.2, c-Met, CD19, PSMA, Muc1, BCMA and PDL1. Here we will introduce a new ADC target trophoblast glycoprotein (TPBG).
Deadenylase Expression in Small Cell Lung Cancer Related To Clinical Characte...JohnJulie1
Lung cancer is the second common malignancy and the most aggressive cancer worldwide with late diagnosis and poor prognosis. The search for biomarkers that promote early diagnosis and improve therapeutic strategies focuses to the understanding of the mechanisms underlying cancer development and progression. The deregulation of gene expression is one of the cancer hallmarks reflected to the stability...
Deadenylase Expression in Small Cell Lung Cancer Related To Clinical Characte...AnonIshanvi
Lung cancer is the second common malignancy and the most aggressive cancer worldwide with late diagnosis and poor prognosis. The search for biomarkers that promote early diagnosis and improve therapeutic strategies focuses to the understanding of the mechanisms underlying cancer development and progression
Deadenylase Expression in Small Cell Lung Cancer Related To Clinical Characte...daranisaha
Lung cancer is the second common malignancy and the most aggressive cancer worldwide with late diagnosis and poor prognosis. The search for biomarkers that promote early diagnosis and improve therapeutic strategies focuses to the understanding of the mechanisms underlying cancer development and progression. The deregulation of gene expression is one of the cancer hallmarks reflected to the stability...
Deadenylase Expression in Small Cell Lung Cancer Related To Clinical Characte...EditorSara
Lung cancer is the second common malignancy and the most aggressive cancer worldwide with late diagnosis and poor prognosis. The search for biomarkers that promote early diagnosis and improve therapeutic strategies focuses to the understanding of the mechanisms underlying cancer development and progression. The deregulation of gene expression is one of the cancer hallmarks reflected to the stability..
Deadenylase Expression in Small Cell Lung Cancer Related To Clinical Characte...NainaAnon
Lung cancer is the second common malignancy and the most aggressive cancer worldwide with late diagnosis and poor prognosis. The search for biomarkers that promote early diagnosis and improve therapeutic strategies focuses to the understanding of the mechanisms underlying cancer development and progression. The deregulation of gene expression is one of the cancer hallmarks reflected to the stability...
Deadenylase Expression in Small Cell Lung Cancer Related To Clinical Characte...semualkaira
Lung cancer is the second common malignancy and the most aggressive cancer worldwide with late diagnosis and poor prognosis. The search for biomarkers that promote early diagnosis and improve therapeutic strategies focuses to the understanding of the mechanisms underlying cancer development and progression. The deregulation of gene expression is one of the cancer hallmarks reflected to the stability...
Similar to Overview of New Targets For Anti-tumor Drugs.pdf (20)
Cyclic Peptides Current Status & Future Prospects.pdfDoriaFang
Researchers have made unremitting efforts to optimize peptides in order to improve the bioavailability of peptide drugs. Cyclization of peptides is one of the methods to optimize peptides. Cyclic peptides combine several favorable properties such as good binding affinity, target selectivity and low toxicity that make them an attractive modality for the development of therapeutics.
Antibody–Oligonucleotide Conjugates (AOCs) in Clinical Trials.pdfDoriaFang
Summary of Antibody–Oligonucleotide Conjugates(AOCs) in Clinical Trials, including products from Avidity Biosciences, Dyne Therapeutics, Tallac Therapeutics and Denali Therapeutics.
Alzheimer's Disease Drug Development Aducanumab, Lecanemab & Donanemab.pdfDoriaFang
Alzheimer's disease (AD) is a neurodegenerative disorder marked by cognitive and behavioral impairment. Here we introduce the development of AD drugs (Aducanumab, Lecanemab & Donanemab).
Summary of Targeted Protein Degradation in Clinical Trials.pdfDoriaFang
Summary of targeted protein degradation, such as PROTAC and molecular glues in clinical trials. PROTAC and molecular glues are the two main modes of TPD technology based on the UPS.
Cleavable Linkers Used In ADC Development.pdfDoriaFang
The linker used in ADC is divided into two types: cleavable linker and non-cleavable linker. This artile mainly introduced the cleavable linkers used in ADC development.
The Role of Four Lipid Components Of LNPs.pdfDoriaFang
LNP consists of four components: ionizable cationic lipids, phospholipids, cholesterol, and PEG lipids. Each component plays a key role in terms of LNP preparations.
Similar to HER2, Trop-2 is a new hot target for research. Trodelvy has been one of the products receiving much attention in recent years, and Dato-DXd from AstraZeneca/Daiichi Sankyo is also advancing rapidly.
DS-8201 (Enhertu) A Potential ADC Drug Targeting HER2.pdfDoriaFang
Enhertu (fam-Trastuzumab deruxtecan-nxki) is a HER2-targeting ADC drug jointly developed by AstraZeneca and Daiichi Sankyo, also known as DS-8201 or T-DXd.
List of New Anti-cancer Drugs Approved By FDA In The First Half of 2023.pdfDoriaFang
What are the new anti-cancer drugs approved in the first half of the year? The new drugs approved covered a variety of solid tumors and blood tumor types.
Summary of ADC Targets For Solid Tumors & Hematological Tumors.pdfDoriaFang
Currently, popular targets include CD family, BCMA, HER2, TROP2, Tissue factor, Nectin-4, FRα, EGFR, etc. Here, we briefly introduce ADC targets in solid tumors and hematological tumors.
New Oncology Trends ADCs, Bispecific Antibodies & CAR-T Cell.pdfDoriaFang
Scientists are turning their attention to more innovative therapeutic strategies, such as next-generation ADCs, bispecific antibodies and CAR-T cell therapies, etc. as cancer therapy.
Summary of Treatments for Multiple Myeloma.pdfDoriaFang
Currently, there are a variety of drugs available for multiple myeloma, including traditional cytotoxic drugs, immunomodulatory analogs, proteasome inhibitors, antibody-based drugs and CAR T-cell therapy.
PROTAC Delivery System Recent Research Advances.pdfDoriaFang
The combination of PROTAC and multifunctional delivery systems will open up new research directions in the field of TPD. Here we will introduce the combination of PROTAC and multifunctional delivery systems.
Buy Verified PayPal Account | Buy Google 5 Star Reviewsusawebmarket
Buy Verified PayPal Account
Looking to buy verified PayPal accounts? Discover 7 expert tips for safely purchasing a verified PayPal account in 2024. Ensure security and reliability for your transactions.
PayPal Services Features-
🟢 Email Access
🟢 Bank Added
🟢 Card Verified
🟢 Full SSN Provided
🟢 Phone Number Access
🟢 Driving License Copy
🟢 Fasted Delivery
Client Satisfaction is Our First priority. Our services is very appropriate to buy. We assume that the first-rate way to purchase our offerings is to order on the website. If you have any worry in our cooperation usually You can order us on Skype or Telegram.
24/7 Hours Reply/Please Contact
usawebmarketEmail: support@usawebmarket.com
Skype: usawebmarket
Telegram: @usawebmarket
WhatsApp: +1(218) 203-5951
USA WEB MARKET is the Best Verified PayPal, Payoneer, Cash App, Skrill, Neteller, Stripe Account and SEO, SMM Service provider.100%Satisfection granted.100% replacement Granted.
Affordable Stationery Printing Services in Jaipur | Navpack n PrintNavpack & Print
Looking for professional printing services in Jaipur? Navpack n Print offers high-quality and affordable stationery printing for all your business needs. Stand out with custom stationery designs and fast turnaround times. Contact us today for a quote!
Business Valuation Principles for EntrepreneursBen Wann
This insightful presentation is designed to equip entrepreneurs with the essential knowledge and tools needed to accurately value their businesses. Understanding business valuation is crucial for making informed decisions, whether you're seeking investment, planning to sell, or simply want to gauge your company's worth.
3.0 Project 2_ Developing My Brand Identity Kit.pptxtanyjahb
A personal brand exploration presentation summarizes an individual's unique qualities and goals, covering strengths, values, passions, and target audience. It helps individuals understand what makes them stand out, their desired image, and how they aim to achieve it.
VAT Registration Outlined In UAE: Benefits and Requirementsuae taxgpt
Vat Registration is a legal obligation for businesses meeting the threshold requirement, helping companies avoid fines and ramifications. Contact now!
https://viralsocialtrends.com/vat-registration-outlined-in-uae/
Putting the SPARK into Virtual Training.pptxCynthia Clay
This 60-minute webinar, sponsored by Adobe, was delivered for the Training Mag Network. It explored the five elements of SPARK: Storytelling, Purpose, Action, Relationships, and Kudos. Knowing how to tell a well-structured story is key to building long-term memory. Stating a clear purpose that doesn't take away from the discovery learning process is critical. Ensuring that people move from theory to practical application is imperative. Creating strong social learning is the key to commitment and engagement. Validating and affirming participants' comments is the way to create a positive learning environment.
Enterprise Excellence is Inclusive Excellence.pdfKaiNexus
Enterprise excellence and inclusive excellence are closely linked, and real-world challenges have shown that both are essential to the success of any organization. To achieve enterprise excellence, organizations must focus on improving their operations and processes while creating an inclusive environment that engages everyone. In this interactive session, the facilitator will highlight commonly established business practices and how they limit our ability to engage everyone every day. More importantly, though, participants will likely gain increased awareness of what we can do differently to maximize enterprise excellence through deliberate inclusion.
What is Enterprise Excellence?
Enterprise Excellence is a holistic approach that's aimed at achieving world-class performance across all aspects of the organization.
What might I learn?
A way to engage all in creating Inclusive Excellence. Lessons from the US military and their parallels to the story of Harry Potter. How belt systems and CI teams can destroy inclusive practices. How leadership language invites people to the party. There are three things leaders can do to engage everyone every day: maximizing psychological safety to create environments where folks learn, contribute, and challenge the status quo.
Who might benefit? Anyone and everyone leading folks from the shop floor to top floor.
Dr. William Harvey is a seasoned Operations Leader with extensive experience in chemical processing, manufacturing, and operations management. At Michelman, he currently oversees multiple sites, leading teams in strategic planning and coaching/practicing continuous improvement. William is set to start his eighth year of teaching at the University of Cincinnati where he teaches marketing, finance, and management. William holds various certifications in change management, quality, leadership, operational excellence, team building, and DiSC, among others.
Falcon stands out as a top-tier P2P Invoice Discounting platform in India, bridging esteemed blue-chip companies and eager investors. Our goal is to transform the investment landscape in India by establishing a comprehensive destination for borrowers and investors with diverse profiles and needs, all while minimizing risk. What sets Falcon apart is the elimination of intermediaries such as commercial banks and depository institutions, allowing investors to enjoy higher yields.
Memorandum Of Association Constitution of Company.pptseri bangash
www.seribangash.com
A Memorandum of Association (MOA) is a legal document that outlines the fundamental principles and objectives upon which a company operates. It serves as the company's charter or constitution and defines the scope of its activities. Here's a detailed note on the MOA:
Contents of Memorandum of Association:
Name Clause: This clause states the name of the company, which should end with words like "Limited" or "Ltd." for a public limited company and "Private Limited" or "Pvt. Ltd." for a private limited company.
https://seribangash.com/article-of-association-is-legal-doc-of-company/
Registered Office Clause: It specifies the location where the company's registered office is situated. This office is where all official communications and notices are sent.
Objective Clause: This clause delineates the main objectives for which the company is formed. It's important to define these objectives clearly, as the company cannot undertake activities beyond those mentioned in this clause.
www.seribangash.com
Liability Clause: It outlines the extent of liability of the company's members. In the case of companies limited by shares, the liability of members is limited to the amount unpaid on their shares. For companies limited by guarantee, members' liability is limited to the amount they undertake to contribute if the company is wound up.
https://seribangash.com/promotors-is-person-conceived-formation-company/
Capital Clause: This clause specifies the authorized capital of the company, i.e., the maximum amount of share capital the company is authorized to issue. It also mentions the division of this capital into shares and their respective nominal value.
Association Clause: It simply states that the subscribers wish to form a company and agree to become members of it, in accordance with the terms of the MOA.
Importance of Memorandum of Association:
Legal Requirement: The MOA is a legal requirement for the formation of a company. It must be filed with the Registrar of Companies during the incorporation process.
Constitutional Document: It serves as the company's constitutional document, defining its scope, powers, and limitations.
Protection of Members: It protects the interests of the company's members by clearly defining the objectives and limiting their liability.
External Communication: It provides clarity to external parties, such as investors, creditors, and regulatory authorities, regarding the company's objectives and powers.
https://seribangash.com/difference-public-and-private-company-law/
Binding Authority: The company and its members are bound by the provisions of the MOA. Any action taken beyond its scope may be considered ultra vires (beyond the powers) of the company and therefore void.
Amendment of MOA:
While the MOA lays down the company's fundamental principles, it is not entirely immutable. It can be amended, but only under specific circumstances and in compliance with legal procedures. Amendments typically require shareholder
RMD24 | Retail media: hoe zet je dit in als je geen AH of Unilever bent? Heid...BBPMedia1
Grote partijen zijn al een tijdje onderweg met retail media. Ondertussen worden in dit domein ook de kansen zichtbaar voor andere spelers in de markt. Maar met die kansen ontstaan ook vragen: Zelf retail media worden of erop adverteren? In welke fase van de funnel past het en hoe integreer je het in een mediaplan? Wat is nu precies het verschil met marketplaces en Programmatic ads? In dit half uur beslechten we de dilemma's en krijg je antwoorden op wanneer het voor jou tijd is om de volgende stap te zetten.
Premium MEAN Stack Development Solutions for Modern BusinessesSynapseIndia
Stay ahead of the curve with our premium MEAN Stack Development Solutions. Our expert developers utilize MongoDB, Express.js, AngularJS, and Node.js to create modern and responsive web applications. Trust us for cutting-edge solutions that drive your business growth and success.
Know more: https://www.synapseindia.com/technology/mean-stack-development-company.html
Tata Group Dials Taiwan for Its Chipmaking Ambition in Gujarat’s DholeraAvirahi City Dholera
The Tata Group, a titan of Indian industry, is making waves with its advanced talks with Taiwanese chipmakers Powerchip Semiconductor Manufacturing Corporation (PSMC) and UMC Group. The goal? Establishing a cutting-edge semiconductor fabrication unit (fab) in Dholera, Gujarat. This isn’t just any project; it’s a potential game changer for India’s chipmaking aspirations and a boon for investors seeking promising residential projects in dholera sir.
Visit : https://www.avirahi.com/blog/tata-group-dials-taiwan-for-its-chipmaking-ambition-in-gujarats-dholera/
What is the TDS Return Filing Due Date for FY 2024-25.pdfseoforlegalpillers
It is crucial for the taxpayers to understand about the TDS Return Filing Due Date, so that they can fulfill your TDS obligations efficiently. Taxpayers can avoid penalties by sticking to the deadlines and by accurate filing of TDS. Timely filing of TDS will make sure about the availability of tax credits. You can also seek the professional guidance of experts like Legal Pillers for timely filing of the TDS Return.
What is the TDS Return Filing Due Date for FY 2024-25.pdf
Overview of New Targets For Anti-tumor Drugs.pdf
1. Huateng Pharma https://us.huatengsci.com
Overview of New Targets For Anti-tumor
Drugs
In the research and development of anti-tumor drugs, the target is undoubtedly
one of the key factors to determine its success. The continuous emergence of
new targets is of great significance for tumor treatment, gradually realizing
precision medicine methods, overcoming drug resistance, and expanding the
therapeutic field.
At present, the treatment of cancer patients still faces many challenges. For
example, targeted therapies such as small molecule drugs and PD-1/L1
inhibitors are only effective for some patients. CAR-T cell therapy products
have only made breakthroughs in the field of blood cancers. In addition, after
cancer patients receive existing drug treatment, many will inevitably have
recurrence, drug resistance and so on. To this end, some scientists are
working hard to find new targets for cancer treatment in order to bring new
treatment options to patients.
In this article, we will summarize the anti-tumor drug targets that have been
newly discovered or have new indications recently.
1. Target For Lung Squamous Cell Carcinoma: mTOR
Non-small cell lung cancer (NSCLC) has always been an important area of
targeted therapy. At present, many targeted drugs can only benefit patients
with lung adenocarcinoma, while another major lung cancer subtype -
squamous cell carcinoma of the lung, only a small number of patients can
receive targeted therapy.
Sapanisertib achieved an objective response rate of 27% and a median
progression-free survival of 8.9 months in patients with advanced refractory
lung squamous cell carcinoma by targeting the mTOR molecule downstream
of the KEAP1/NRF2 pathway.
Currently, Sapanisertib combined with PD-1 is being studied in the treatment
of advanced NRF2-mutated lung squamous cell carcinoma.
2. Target For Pancreatic cancer: RBFOX2
Pancreatic ductal adenocarcinoma (PDAC) is a malignant tumor with high
invasiveness and strong metastatic ability. Currently, it is unclear what the
driver mutations that lead to PDAC metastasis are. In an article titled "RBFOX2
modulates a metastatic singature of alternative splicing in pancreatic cancer"
published in Nature on March 22, 2023, the researchers analyzed RNA
splicing data from a large number of primary and metastatic PDAC tumors to
identify differential splicing events associated with PDAC progression and
found highly similar enrichment with RBFOX2 motifs.
Experiments showed that overexpression of RBFOX2 in patient-derived
xenograft (PDX) metastatic PDAC cell lines significantly reduced the ability of
2. Huateng Pharma https://us.huatengsci.com
these cells to metastasize in vitro and in vivo, while depletion of RBFOX2 in
primary pancreatic tumor cell lines increased the metastatic potential of these
cells. These findings suggest that RBFOX2 may have a potential role in
inhibiting PDAC metastasis. Further analysis by RNA sequencing and splicing
revealed that RBFOX2 splicing activity plays a role in the formation of
cytoskeletal organization and fibroblast connections. Among them, splicing of
myosin phosphatase RHO interacting protein (MPRIP) regulated by RBFOX2
has been shown to be associated with PDAC metastasis, cytoskeletal tissue
changes, and induction of fibroblast junction. Thus, precise regulation of
RBFOX2 alternative splicing events, such as MPRIP, may serve as a potential
therapy for PDAC.
Figure 1. RBFOX2 acts as a metastatic tumour suppressor in pancreatic
cancer progression.
(Source: References [1])
This study provides important clues for in-depth understanding of the
metastasis mechanism of PDAC and lays the foundation for utilizing the
splicing regulation of RBFOX2 gene as a potential therapeutic strategy for
PDAC.
3. Target for Glioblastoma: FGL2
As a member of the fibrinogen-like protein family, fibrinogen-like 2 (FGL2) has
prothrombinase activity and immunomodulatory functions in viral infection and
cancer development.
In a paper titled "FGL2-targeting T cells echibit antitumor effects on
glioblastoma and recruit," published in Nature Communications on February
3. Huateng Pharma https://us.huatengsci.com
10, 2023 In the "tumor-specific brain-resident memory T cells", the researchers
found that the expression of FGL2-specific T cells with a single-chain variable
fragment (T-αFGL2) can induce tumor-specific CD8+ tissue-resident memory
T (TRM) cells, thereby preventing glioblastoma recurrence.
These CD8+TRM cells showed a highly expanded library of T cell receptors,
unlike those found in peripheral tissue. When adoptively transferred to the
brains of immature mice with immunoactive or T-cell deficiencies, these CD8+
TRM cells rejected glioma cells. In terms of mechanism of action, T-αFGL2 cell
therapy increased the number of CD69+CD8+ brain-resident memory T cells
in tumor-bearing mice through CXCL9/10 and CXCR3 chemokine signaling.
These findings suggest that tumor-specific brain-resident CD8+TRM cells may
have important implications for preventing brain tumor recurrence.
Figure 2. Antitumor activity of T-αFGL2 in vivo.
(Source: References [2])
Therefore, FGL2 is considered an attractive target for glioblastoma
immunotherapy.
4. New Target For Gastric Cancer: Claudin-18.2
Claudin-18.2 (CLDN 18.2) is a tight junction protein widely present in gastric
mucosa. Under normal circumstances, it is responsible for firmly connecting
adjacent gastric mucosal epithelial cells together, preventing food and
digestive juices in the stomach from leaking out of the cell space into the
human internal environment.
However, during tumor development, CLDN 18.2 is widely expressed in a
variety of gastrointestinal tumors and participates in tumor proliferation,
differentiation and migration.
At present, a variety of drugs targeting CLDN 18.2 are under research at home
and abroad. Zolbetuximab is the first drug targeting CLDN 18.2. Compared
4. Huateng Pharma https://us.huatengsci.com
with mFLOFOX6 chemotherapy alone, adding Zolbetuximab and mFLOFOX6
chemotherapy, the median progression-free survival of patients with advanced
gastric cancer was extended by nearly 2 months to 10.61 months, and the
median overall survival was extended from 15.54 months to 18.23 months.
Both the risk of death and the risk of progression were reduced by 25%.
5. New Targets For Liver Cancer: SULT1A1, PRRS35
Liver malignancies in adults, including intrahepatic cholangiocarcinoma (ICC)
and hepatocellular carcinoma (HCC), are the second leading cause of
cancer-related death worldwide. For patients with advanced ICC, the standard
treatment is combination chemotherapy. For patients with advanced HCC,
standard treatment is combined immunotherapy/multikinase inhibitors. Most
received combination chemotherapy or immunotherapy, respectively, without
specific biomarkers to choose from. Although these treatments have improved
the response rate and overall survival of patients, the effect is still poor.
(1) SULT1A1: An article titled "SULT1A1-dependent suslfonation of alkylators
is a Lineage-dependent vulnerability of liver cancers" published in Nature
Cancer on March 13, 2023. This article presents the results of research on
adult liver malignancies, including intrahepatic cholangiocarcinoma and
hepatocellular carcinoma. In this study, through high-throughput screening,
proteomics, and in vitro resistance models, the researchers identified a small
molecule compound called YC-1 that has selective activity against cell line
subpopulations from two liver cancer types.
This article presents the results of research on adult liver malignancies,
including intrahepatic cholangiocarcinoma and hepatocellular carcinoma. In
this study, through high-throughput screening, proteomics, and in vitro
resistance models, the researchers identified a small molecule compound
called YC-1 that has selective activity against cell line subpopulations from two
liver cancer types.
The data demonstrated that this selective activity is associated with the
expression of the liver-intrinsic cytoplasmic sulfotransferase SULT1A1.
Through computational analysis, the researchers also identified a broader
class of anticancer compounds that depend on SULT1A1. This study suggests
that SULT1A1 has the potential to be a potential new target for liver cancer
drug development.
5. Huateng Pharma https://us.huatengsci.com
Figure 3. Identification of selective YC-1 activity against liver cancer subsets.
(Source: References [3])
(2) PRRS35: Liver cells mainly function by secreting proteins that regulate cell
proliferation, metabolism and intercellular communication. During the
progression of hepatocellular carcinoma (HCC), the hepatocyte secretome is
dynamically altered, which is both a consequence and a causative factor of
tumorigenesis.
An article entitled "Secreted protease PRSS35 suppresses hepatocellular
carcinoma by disabling CXCL2-mediated neutrophil extracellular traps"
published in Nature Communications on March 18, 2023 reveals the tumor
suppressor effect of protease PRSS35 in hepatocellular carcinoma.
Studies have shown that active PRSS35 can inhibit the protein level of CXCL2,
thereby inhibiting the progression of HCC. This study expands our
understanding of the role of the hepatocyte secretome in cancer development
and provides the basis for clinical translation of PRSS35 as a therapeutic
target or diagnostic biomarker.
6. Huateng Pharma https://us.huatengsci.com
Figure 4. PRSS35 is a secreted protein that decreased in HCC patients
(Source: References [4])
6. New Targets For Prostate Cancer: PI5P4Kα, PODXL, TRABID
(1) PI5P4Kα: Phosphatidylinositol (PI) regulatory enzymes are often altered in
cancer and have become a key research object for drug development, and it is
an important target for anticancer drug research.
On February 1, 2023, an article entitled "PI5P4Kɑ supports prostate cancer
metabolism and exposes a survival vulnerability during androgen receptor
inhibition" was published on Science Advances. Researchers investigated the
7. Huateng Pharma https://us.huatengsci.com
function of phosphatidylinositol-5-phosphate-4-kinase (PI5P4K) an validated
the effect of the PI5P4Kα isoform on androgen receptor (AR) signaling, a
signaling pathway that supports prostate cancer cell survival.
Figure 5. PIP4K2A expression correlates with low androgen receptor signaling
(Source: References [5])
(2) PODXL: glycocalyx component and salivary mucin pocalylin (PODXL) is a
transmembrane protein whose elevated expression is associated with poor
clinical outcomes in tumors, leading scientists to think that it might serve as a
mechanism for cancer metastasis targeted biomarkers. Given that PODXL is
also required for function in normal tissues, it is imperative to determine the
tumor-specific environment that regulates PODXL function.
On February 3, 2023, an article entitled "Spetial regulation of the glycocalyx
component podocalyxin is a switch for prometastaic function" was published
8. Huateng Pharma https://us.huatengsci.com
on Science Advances. The study identified an unexpected function of PODXL
as a decoy receptor for galactin-3 (GAL3), in which PodxL-GAL3 interaction
releases GAL3 to inhibit integrin-based invasion. Through experiments, the
researchers identified the molecular mechanism that controls the transition of
PODXL to the transmission-promoting glycocalyx component, while revealing
that PODXL acts as a decoy receptor to mitigate the invasion inhibition of
GAL3, and demonstrating that this level of change can be used to identify
prostate cancer patients with high metastasis and poor prognosis.
Figure 6. PODXL promotes the formation of invasive tunnels in the ECM
(Source: References [6])
9. Huateng Pharma https://us.huatengsci.com
(3) TRABID: On March 31, 2023, a paper entitled "TRABID overexpression
enables synthetic lethality to PAPR inhibitor via prolonging 53BP1 retention at
double-strand breaks" was published in Nature Communications.
Studies have demonstrated that TRABID deubiquitinase can bind to 53BP1
and regulate the stabilization of 53BP1 at double-strand break sites. When
TRABID was overexpressed in prostate cancer cells, the cancer cells showed
high sensitivity to PARP inhibitors.
The study noted that TRABID promoted non-homologous end-joining repair
rather than homologous recombination by prolonging the presence of 53BP1
at the double-strand break sites, suggesting that TRABID overexpression can
be used as a predictor of homologous recombination defects in prostate
cancer and the therapeutic potential of PARP inhibitors.
Figure 7. TRABID regulates 53BP1 foci formation at DSB sites
(Source: References 7])
Conclusion
In addition to these targets mentioned above, there are also applications of
new targets in the treatment of other tumors. For example, at the ASCO
conference in 2023, Professor Christina Wu from the Mayo Medical Center
studied four novel therapeutic targets in colorectal cancer (CRC). Important
clinical studies including HER2 amplification, KRAS G12C mutation, NTRK
fusion and RET fusion were summarized and reported. In terms of ADC drugs,
many targets have also been used, such as FolRa, TROP2, ITGB6, etc.
The identification of new targets of drugs is of great significance to advancing
cancer treatment, and provides a new option for overcoming drug resistance
and realizing precision medicine. Continued research and innovation in this
10. Huateng Pharma https://us.huatengsci.com
area will help provide more effective, targeted and personalized treatments for
cancer patients, ultimately improving patient outcomes and quality of life.
As a reliable pharmaceutical intermediates supplier, Huateng Pharma is
dedicated to manufacturing and supplying a varieties of anti-cancer API
intermediates for customers all over the world, such as Alectinib
intermediates for the treatment of non-small-cell lung cancer
(NSCLC), Carfilzomib intermediates for the treatment of relapsed or
refractory multiple myeloma, Enzalutamide intermediates for the treatment
of prostate cancer, Pralatrexate intermediates for the treatment of lymphoma,
non-small-cell lung cancer, breast cancer, and bladder cancer.
References:
[1]. RBFOX2 modulates a metastatic signature of alternative splicing in
pancreatic cancer. Retrieved Mar 22, 2023, from
https://www.nature.com/articles/s41586-023-05820-3
[2]. FGL2-targeting T cells exhibit antitumor effects on glioblastoma and recruit
tumor-specific brain resident memory T cells. Retrieved Feb 10, 2023, from
https://www.nature.com/articles/s41467-023-36430-2
[3]. SULT1A1-dependent sulfonation of alkylators is a lineage-dependent
vulnerability of liver cancers. Retrieved Mar 13, 2023, from
https://www.nature.com/articles/s43018-023-00523-0
[4]. Secreted protease PRSS35 suppresses the hepatocellular carcinoma by
disabling CXCL2-mediated neutrophil extracellular traps. Retrieved Mar 18,
2023, from https://www.nature.com/articles/s41467-023-37227-z
[5]. PI5P4Kα supports prostate cancer metabolism and exposes a survival
vulnerability during androgen receptor inhibition. Retrieved Feb 01, 2023, from
https://www.science.org/doi/10.1126/sciadv.ade8641
[6]. Spatial regulation of the glycocalyx component podocalyxin is a switch for
prometastatic function. Retrieved Feb 03, 2023, from
https://www.science.org/doi/10.1126/sciadv.abq1858
[7]. TRABID overexpression enables synthetic lethality to parp inhibitor via
prolonging 53BP1 retention at double-strand breaks. Retrieved Mar 31, 2023,
from https://www.nature.com/articles/s41467-023-37499-5
Related articles:
List of New Anti-cancer Drugs Approved By FDA In The First Half of 2023